Articles tagged with Insulin
A recent study found that many people with type 2 diabetes know little about their condition, highlighting the need to improve communication and disease knowledge. The study revealed significant gaps in knowledge, particularly regarding blood sugar monitoring and late-stage complications like ketoacidosis.
A new study from Uppsala University found that adults who sleep only three to five hours a day are at higher risk of developing type 2 diabetes. Chronic sleep deprivation cannot be compensated by healthy eating alone.
A Boston College biologist is studying the mechanisms of viral insulins to develop novel therapeutics for a range of human diseases, including cancers. The researcher has identified six viruses that mimic human insulin and IGF-1, which can block an important receptor, leading to potential affordable treatments.
A new RAND report finds that US insulin prices are more than nine times higher than in 33 high-income countries. After accounting for rebates and discounts, US net prices remained 2.3 times higher. The study updates earlier findings on US insulin prices and highlights the need for policy changes to address these disparities.
Researchers have developed a new oral insulin medicine that uses nano-carriers to protect insulin from stomach acid, allowing for precise delivery to the liver and reducing the risk of hypoglycemia. This innovation has been successfully tested on baboons, mice, and rats with diabetes, paving the way for human trials starting in 2025.
Researchers identified a significant decrease in insulin-producing beta cells with increasing age, correlating with pancreatic intraepithelial neoplasias. The study suggests that islet cell loss may be a key driver of senile diabetes, informing potential preventative treatments.
Researchers discovered that fruit bats have a genetic system controlling blood sugar levels, allowing them to consume up to twice their body weight in sugary fruit daily. The study's findings may lead to the development of better insulin- or sugar-sensing therapies for people with diabetes.
A recent study by the Hebrew University proposes a new etiology for early stages of type 1 diabetes, attributing it to disrupted RNA editing within pancreatic beta cells. This perspective challenges long-held beliefs about viral involvement, suggesting potential implications for treatments and cures.
A moderate low-carbohydrate diet has been shown to lower average blood sugar levels and increase time spent within the target glucose range without adverse effects. Participants experienced improved glucose control and felt more satisfied with the new diet.
Using metformin plus insulin to treat preexisting type 2 or gestational diabetes diagnosed early in pregnancy did not show a reduction in composite neonatal adverse outcomes. The study suggests that the effect of reducing large-for-gestational-age infant risk after adding metformin to insulin warrants further investigation.
A Northwestern University study found that nearly two-thirds of patients discontinue or change their medication within a year, highlighting the need for better understanding of barriers to treatment adherence. The high discontinuation rate for GLP-1 RAs may be due to gastrointestinal side effects.
A new study found no increased risk of major congenital malformations in infants exposed to second-line non-insulin antidiabetic medications during pregnancy compared to those treated with insulin. The study examined over 3.5 million pregnancies and provided reassurance on the safety of these medications for fetuses.
A world-first human trial shows that a commonly prescribed rheumatoid arthritis drug can safely and effectively preserve the body's own insulin production and suppress the progression of type 1 diabetes. The drug, baricitinib, was found to be effective in maintaining insulin production in people who initiated treatment within 100 days ...
Researchers at the University of Alberta and Cornell University have developed a device that can secrete insulin under the skin, improving cell survival and diabetes reversal in mice. The innovative approach called SHEATH avoids immunosuppression, making transplants safer for patients with type 1 diabetes.
Researchers from Cornell and University of Alberta have developed an under-the-skin implant that can secrete insulin without immunosuppression. The approach offers an easier alternative to traditional transplants or insulin injections, with the potential for long-term management of Type I diabetes.
In a significant breakthrough, research revealed that macrophages 'eat' pancreatic beta cells to regulate insulin levels after pregnancy. This process helps maintain normal blood glucose levels.
Researchers at Tohoku University successfully regenerated pancreatic beta-cells in mice by stimulating autonomic vagal nerves connected to the pancreas. This innovative approach improved insulin function and increased beta-cell numbers, ameliorating diabetes symptoms.
A new clinical trial has shown that a stem cell-based device can reduce the amount of insulin required for some participants with Type 1 diabetes. The device, developed by ViaCyte, aims to replace the insulin-producing beta cells that people with the condition lack.
Researchers at the University of Tsukuba discovered a novel pathway where pancreatic beta-cells undergo dedifferentiation and differentiate into acinar-like cells, contributing to insulin secretory capacity reduction. The study also identified Anxa10 as a key gene upregulated in pancreatic beta-cells during diabetes onset.
Researchers analyzed FDA and patent records to find that manufacturers extended market exclusivity by filing additional patents after FDA approval and obtaining patents on delivery devices. This resulted in a median of 16 years of protection, surpassing other top-selling small-molecule drugs.
Researchers discovered that individuals with obesity expel more energy at night compared to those with a healthy weight. During the day, people with obesity have higher insulin levels, indicating their body is working harder to process glucose.
A drug currently in clinical trials as a cancer therapy can also stimulate pancreatic beta cells to secrete insulin, revealing a new mechanism for insulin regulation in type 2 diabetes. The preclinical discovery provides a new chemical tool for probing the biology of diabetes and could lead to better treatments.
Researchers at the University of Alberta have created a new process to produce insulin-producing pancreatic cells from patient stem cells, achieving a 90% success rate. The breakthrough could lead to injection-free glucose control in people with diabetes and eliminate the need for anti-rejection drugs.
A new Cochrane review has found that human insulin can be stored at room temperature for up to six months without losing potency. This breakthrough research offers hope to millions of people living with diabetes in low- and middle-income countries, particularly those with limited access to refrigeration or healthcare.
Researchers at University of British Columbia find a direct link between high insulin levels and pancreatic cancer, highlighting the importance of keeping insulin levels within a healthy range. The study suggests that excessive insulin overstimulates pancreatic acinar cells, leading to inflammation and precancerous cell development.
A new phase 3 clinical trial found that once-weekly basal injection of icodec to treat type 1 diabetes showed non-inferiority to daily insulin degludec in reducing HbA1C levels. However, higher rates of hypoglycaemic episodes were noted in the icodec group.
A new study published in the University of East Anglia shows that automated insulin delivery technology can help pregnant women with type 1 diabetes better manage their blood sugars. The technology, known as Hybrid Closed-Loop or Artificial Pancreas, helps to substantially reduce maternal blood sugars throughout pregnancy.
A new study found that hybrid closed-loop technology significantly improved maternal blood sugars in pregnant women with type 1 diabetes. Women who used the technology spent more time within the target range for pregnancy blood sugar levels, gained less weight, and had fewer complications.
Research reveals that faster placental growth increases the risk of preeclampsia and shorter pregnancy duration. Genetic variations affecting placental size also influence baby weight and mother's health.
A new study published in Diabetologia found that hybrid closed-loop technology improved maternal blood sugars during pregnancy complicated by type 1 diabetes. The technology, which adjusts insulin doses every 10-12 minutes, helped reduce maternal blood sugar levels and weight gain, while also improving baby health outcomes.
A phase 1/2 study shows that a stem cell-derived islet therapy has improved blood sugar control in all six adult patients with type 1 diabetes. Three patients achieved insulin independence and showed sustained improvements in blood glucose levels.
Research suggests that universal screening for type 1 diabetes at two ages could predict most cases of T1D by age 15. Dr. Emily K. Sims emphasizes the importance of identifying individuals with early, presymptomatic stages of disease to prevent life-threatening episodes and improve outcomes.
A new clinical trial has found that administering metformin to pregnant women with gestational diabetes does not increase adverse neonatal outcomes or maternal health risks. The study provides hope for expectant mothers and healthcare providers seeking a safe alternative to traditional insulin-based treatments.
A randomized clinical trial found that early metformin treatment did not improve insulin initiation or fasting glucose levels in pregnant women with gestational diabetes. Further investigation into larger trials is warranted based on prespecified secondary outcome data.
A study of over 1 million Swedish men found that high blood pressure at age 18 was associated with a higher risk of major cardiovascular events, including heart failure, heart attacks, and strokes. Early intervention for hypertension may be critical to reducing later cardiovascular events.
Researchers developed a computational model to analyze glucose-responsive insulin (GRI) performance in human patients. The model predicted that differences in sugar receptor behavior between humans and lab animals led to the drug's poor effect in clinical trials. This breakthrough helps researchers design better GRIs, potentially reduc...
Researchers have designed an implantable device that carries hundreds of thousands of insulin-producing islet cells and has its own on-board oxygen factory, generating oxygen by splitting water vapor. The device was tested in diabetic mice and maintained normal blood glucose levels for at least a month.
A recent study published in the Journal of Diabetes Science and Technology found that HbA1c levels are markedly higher in young black youth compared to whites with type 1 diabetes. This disparity can lead to increased risk of hypoglycemia and long-term complications if primarily used for insulin management.
A comprehensive study reveals that genetics and diet significantly influence insulin signaling in skeletal muscle. The research identified thousands of novel phosphosites associated with insulin regulation and provided a unique tool for assessing phosphorylation in insulin reactions.
A small study found that treating newly diagnosed Type 1 diabetes patients with semaglutide significantly reduced their need for insulin. The medication's ability to stimulate insulin secretion from the beta cells of the pancreas allowed for the elimination of mealtime and basal insulin doses in most patients.
Researchers discovered a gut bacteria that helps reduce insulin resistance and protect against diabetes. The study found that a specific bacteria, Alistipes indistinctus, consumed excess monosaccharides in the gut, lowering blood sugar levels and reducing insulin resistance.
A new study from the University of Copenhagen reveals that GDF15 improves insulin sensitivity in rodents, particularly in their liver and fatty tissue. This finding raises interesting perspectives for treating type 2 diabetes and high blood pressure, as increased insulin sensitivity is a critical indicator of health.
Researchers at ETH Zurich have developed a gene switch that uses sound waves to trigger insulin release in designer cells. The system works by embedding an ion channel protein from the bacterium E. coli into human cells, which opens in response to sound, causing insulin vesicles to fuse and release insulin.
A recent study by Pennington Biomedical Research Center identifies GDF15 as a protein that acts as a cellular signal to enhance insulin secretion. High-intensity exercise training in patients with type 2 diabetes was found to have elevated levels of GDF15, associated with improved glycemic control.
Researchers found that liraglutide improves associative learning in people with obesity by restoring brain activity to normal-weight levels. The study showed that participants with obesity had reduced ability to associate sensory stimuli and decreased brain activity compared to those with normal weight.
Researchers aim to investigate the link between gut microbes and Type 1 diabetes. Emrah Altindis's lab seeks to understand how a protein found in certain bacteria may trigger the onset of T1D.
A recent study found that patients with type 1 diabetes using insulin pumps for extended periods do not exhibit significantly more pathology in their skin compared to short-term users. Despite this, researchers still struggle to understand the underlying causes of skin damage and inflammation at infusion sites.
A new study found that snacking on high-quality foods can improve blood fat and insulin responses, while late-night snacking may have unfavorable effects. The researchers analyzed data from over 1,000 people in the UK and found no association between snack frequency or calories consumed and health measures.
Researchers at UC Berkeley discovered that deep-sleep brain waves can regulate the body's sensitivity to insulin, improving blood sugar control. The study found that synchronized brain waves during deep sleep predict next-day glucose control, even after controlling for other factors.
A study published in Nature Communications reveals the controlled release of mucins and insulin by cells, with tetraspanin-8 acting as a gatekeeper. The regulated secretion is biphasic, involving rapid and slower releases of granules, which can be targeted to reset deregulated mucin and insulin secretion.
A recent meta-analysis of 29 studies found that intranasal insulin treatment can boost cognition in individuals with mild cognitive impairment or Alzheimer's Disease. The analysis suggests potential benefits for this treatment approach, which may be worth further investigation.
Once-weekly Icodec demonstrated superior HbA1c reduction compared to once-daily Degludec after 26 weeks, but no difference was found in weight change. However, Icodec showed a higher rate of combined level two or three hypoglycemic events
A randomized phase II study found that adding metformin to androgen deprivation therapy did not reduce the risk of metabolic syndrome or improve PSA response in patients with advanced prostate cancer. Metformin showed some antitumor effects through mTOR inhibition, but these were not significant.
Researchers have found a hidden mechanism connecting cancer and diabetes, where cancer cells don't respond well to insulin, leading to faster cancer growth. Insulin resistance can also cause muscle loss and strength decline in cancer patients.
A plant-based, oral delivery of proinsulin regulated blood sugar within 15 minutes similar to naturally secreted insulin in diabetic mice. This method eliminates the need for expensive laboratory equipment and results in a shelf-stable product, making it more affordable and accessible.
A study found that even insured patients with diabetes use crowdfunding platforms like GoFundMe to cover excess medical expenses, including uncovered co-pays and life-saving care. Researchers urge policymakers to consider these needs when developing affordable diabetes care policies.
A study of over 55,000 people identified new genetic variants associated with insulin resistance after eating, which may help inform future treatments of type 2 diabetes. The discovery highlights the importance of understanding how glucose regulation works in the body, particularly in the fed state.
Researchers have discovered molecules in 3,000 diabetic patients that could help predict and monitor disease progression. The study identified 20 biomarkers associated with rapid disease progression, including a protein called NogoR.
Researchers at Weill Cornell Medicine have successfully converted human stomach stem cells into insulin-secreting cells, offering a promising approach to treating type 1 and severe type 2 diabetes. The transplants reversed disease signs in mouse models, suggesting good durability.
Researchers have developed an algorithm that accounts for individual patient differences and validated a pump control algorithm that does not require meal announcement. This innovation simplifies the control problem, reduces delays, and increases the accuracy of insulin delivery, making diabetes management less burdensome for patients.